Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+5.76M
-
Total reported value, excl. options
-
$606M
-
Value change
-
+$185M
-
Number of buys
-
63
-
Number of sells
-
-14
-
Price
-
$31.25
Significant Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q4 2019
87 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2019.
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
of 45.1M outstanding shares and own 43% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (2.46M shares), Sofinnova Investments, Inc. (2.19M shares), BlackRock Inc. (2.01M shares), Cormorant Asset Management, LP (1.6M shares), FMR LLC (1.39M shares), VANGUARD GROUP INC (1.06M shares), ALLIANCEBERNSTEIN L.P. (844K shares), STATE STREET CORP (748K shares), GOLDMAN SACHS GROUP INC (577K shares), and PERCEPTIVE ADVISORS LLC (562K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.